International Clinical Trial: A Multicenter, Randomized, Open Label, Blinded Endpoint Clinical Trial of Methylprednisolone Sodium Succinate in Acute Disabling Non Large Vessel Occlusion Ischemic Stroke (MARVEL-MPSS Study)

Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121588) titled 'A Multicenter, Randomized, Open Label, Blinded Endpoint Clinical Trial of Methylprednisolone Sodium Succinate in Acute Disabling Non Large Vessel Occlusion Ischemic Stroke (MARVEL-MPSS Study)' on April 1.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: The Second Affiliated Hospital of the Army Medical University

Condition: Acute disabling non-large vessel occlusion (non-LVO) ischemic stroke within 24 hours from last known well.

Intervention: Trial Group:Intravenous methylprednisolone sodium succinate (MPSS), 2 mg/kg once daily by drip infusion for 3 consecutive days

Recruitment ...